Abstract：
METHODS: Retrospective Cohort Study.
OBJECTIVE: The primary objective of this study is to evaluate the efficacy of early administration of Teriparatide in preventing the necessity of surgical intervention in individuals with osteoporotic vertebral compression fractures.
METHODS: In a 24-month follow-up retrospective analysis, 191 OVCF patients from January 2016 to October 2020 were randomly assigned to Non teriparatide Group A (n = 104) or Group B teriparatide (n = 87). At baseline, 6 months, 1 year, and 2 years following treatment, demographic data and need of surgical intervention, VAS, ODI, union rates, and kyphosis development, were examined.
RESULTS: Our study found that non-teriparatide group individuals had an 11.53% higher risk of non-union formation that required surgery. Only 8.63% of teriparatide group patients needed surgery. Both groups had significant VAS score reductions. Non-teriparatide group scores declined from 8.38 ± 0.74 to 3.15 ± 1.40, while teriparatide group scores decreased from 8.49 ± 0.73 to 1.11 ± 0.31. The 2-year follow-up ODI scores significantly decreased, with values of 25.02 ± 13.94 for non-teriparatide patients and 15.11 ± 2.17 for teriparatide patients. The kyphosis progression angles in the teriparatide group were considerably lower (4.97 ± 0.78°) compared to the other group (8.09 ± 1.25°).
CONCLUSIONS: With increasing elderly populations, it is necessary to take measures to prevent surgical intervention in osteoporotic spinal compression fractures. Teriparatide can be employed as an early medication in the management of these fractures to avert non-union and the minimise the progression of kyphosis.
OBJECTIVE: The primary objective of this study is to evaluate the efficacy of early administration of Teriparatide in preventing the necessity of surgical intervention in individuals with osteoporotic vertebral compression fractures.
METHODS: In a 24-month follow-up retrospective analysis, 191 OVCF patients from January 2016 to October 2020 were randomly assigned to Non teriparatide Group A (n = 104) or Group B teriparatide (n = 87). At baseline, 6 months, 1 year, and 2 years following treatment, demographic data and need of surgical intervention, VAS, ODI, union rates, and kyphosis development, were examined.
RESULTS: Our study found that non-teriparatide group individuals had an 11.53% higher risk of non-union formation that required surgery. Only 8.63% of teriparatide group patients needed surgery. Both groups had significant VAS score reductions. Non-teriparatide group scores declined from 8.38 ± 0.74 to 3.15 ± 1.40, while teriparatide group scores decreased from 8.49 ± 0.73 to 1.11 ± 0.31. The 2-year follow-up ODI scores significantly decreased, with values of 25.02 ± 13.94 for non-teriparatide patients and 15.11 ± 2.17 for teriparatide patients. The kyphosis progression angles in the teriparatide group were considerably lower (4.97 ± 0.78°) compared to the other group (8.09 ± 1.25°).
CONCLUSIONS: With increasing elderly populations, it is necessary to take measures to prevent surgical intervention in osteoporotic spinal compression fractures. Teriparatide can be employed as an early medication in the management of these fractures to avert non-union and the minimise the progression of kyphosis.
摘要：
方法：回顾性队列研究。
目的：本研究的主要目的是评估早期应用特立帕肽预防骨质疏松性椎体压缩性骨折患者手术干预的有效性。
方法：在24个月的随访回顾性分析中，从2016年1月至2020年10月，191名OVCF患者被随机分配到非特帕肽A组（n=104）或特帕肽B组（n=87）。在基线,6个月,1年,治疗2年后，人口统计数据和手术干预的需要，VAS,ODI,工会费率，和后凸的发展，进行了检查。
结果：我们的研究发现，非特立帕肽组个体发生骨不连需要手术的风险高11.53%。只有8.63%的特立帕肽组患者需要手术。两组均有显著的VAS评分降低。非特立帕肽组得分从8.38±0.74下降至3.15±1.40，而特立帕肽组得分从8.49±0.73下降至1.11±0.31。2年随访ODI评分明显下降,非特立帕肽患者的值为25.02±13.94，特立帕肽患者的值为15.11±2.17。特立帕肽组的后凸发展角（4.97±0.78°）明显低于其他组（8.09±1.25°）。
结论：随着老年人口的增加，在骨质疏松性脊柱压缩性骨折中，有必要采取措施预防手术干预。特立帕肽可以用作治疗这些骨折的早期药物，以避免不愈合并最大程度地减少脊柱后凸的进展。
目的：本研究的主要目的是评估早期应用特立帕肽预防骨质疏松性椎体压缩性骨折患者手术干预的有效性。
方法：在24个月的随访回顾性分析中，从2016年1月至2020年10月，191名OVCF患者被随机分配到非特帕肽A组（n=104）或特帕肽B组（n=87）。在基线,6个月,1年,治疗2年后，人口统计数据和手术干预的需要，VAS,ODI,工会费率，和后凸的发展，进行了检查。
结果：我们的研究发现，非特立帕肽组个体发生骨不连需要手术的风险高11.53%。只有8.63%的特立帕肽组患者需要手术。两组均有显著的VAS评分降低。非特立帕肽组得分从8.38±0.74下降至3.15±1.40，而特立帕肽组得分从8.49±0.73下降至1.11±0.31。2年随访ODI评分明显下降,非特立帕肽患者的值为25.02±13.94，特立帕肽患者的值为15.11±2.17。特立帕肽组的后凸发展角（4.97±0.78°）明显低于其他组（8.09±1.25°）。
结论：随着老年人口的增加，在骨质疏松性脊柱压缩性骨折中，有必要采取措施预防手术干预。特立帕肽可以用作治疗这些骨折的早期药物，以避免不愈合并最大程度地减少脊柱后凸的进展。
